If you have suffered a heart attack, other cardiovascular problems, kidney damage or ketoacidosis while taking Invokana (canagliflozin) or Invokamet for Type 2 diabetes, your medication may be the cause. Invokana was approved by the U.S. Food and Drug Administration (FDA) in March 2013, to treat Type 2 diabetes. It was the first in a new class of diabetes medication called sodium-glucose co-transporter 2 (SGLT2) inhibitor. If you have been harmed by Invokana or lost a loved one to the side effects of this drug, you may be able to recover compensation based on the drug company’s failure to warn physicians and patients about the dangers.
Invokana users have suffered injuries including:
- Diabetic ketoacidosis
- Kidney failure or kidney damage serious enough to require transplant
- Abnormal weight loss
- Urinary tract infections
- Yeast infections
When Invokana was approved by the FDA it was in spite of concerns about cardiovascular risks including the risk of stroke. AS part of approval, the FDA required Invokana maker, Janssen Pharmaceuticals, to conduct a post-market study of the cardiovascular risks called Canagliflozin Cardiovascular Assessment Study (CANVAS). The study is to measure the risk of major cardiovascular events including:
- Cardiovascular death
- Nonfatal myocardial infarction
- Nonfatal stroke
No Recall Yet
Invokana has not been recalled, but that is no indication of its safety. One a drug is approved, it can take years of injuries and deaths before any kind of recall is issued, and even then it is usually to update the safety warnings on the label. Withdrawal of a dangerous drug is very rare.